Author/Authors :
-، - نويسنده Preventive Cardiovascular Care Research Center, Imam Reza Hospital, School of Medicine, Mashhad University of Medical
Sciences, Mashhad, Iran Vakilian, Farveh , -، - نويسنده Prenatal Care Research Center, School of Medicine, Omolbanin Hospital, Mashhad University of Medical Sciences, Mashhad,
Iran Tara, Fateme , -، - نويسنده Department of Gynecology, School of Medicine, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Moosavi, Fateme
Abstract :
Heart failure (HF) is a serious and growing public health concern, which has many causes. Pregnancy is a critical condition with significant hemodynamic and immunologic changes. Peripartum cardiomyopathy (PPCM) is a disease of unknown cause in which left ventricular (LV) dysfunction occurs during the last trimester of pregnancy or the early puerperium. PPCM is known to be the most common cardiovascular cause of severe complications in pregnancy. Risk factors for peripartum cardiomyopathy include advanced maternal age, twin pregnancy, smoking, pregnancy-related hypertension and preeclampsia, multiparity, African descent, and long-term tocolysis. Oxidative stress and some inflammatory markers have been diagnosed in PPCM pathophysiology. Recent observations have suggested that bromocriptine might favor recovery of LV systolic function in patients with PPCM. Patients developed peripartum cardiomiopathy treated with bromocriptine showed significantly improved LV ejection fraction and heart failure symptoms. This article tries to have a short review on this clinical scenario.
